Correlation Engine 2.0
Clear Search sequence regions

  • adenocarcinoma (1)
  • ASCL1 (13)
  • ascl1 protein, human (1)
  • CCL20 (1)
  • CCR6 (1)
  • CD163 (1)
  • CD20 (1)
  • chemotaxis (1)
  • CXCL10 (1)
  • CXCL16 (1)
  • CXCL2 (1)
  • CXCR3 (1)
  • cyclin (1)
  • factors (2)
  • FOXP3 (1)
  • humans (1)
  • lung (2)
  • lung adenocarcinoma (6)
  • lung cancer (1)
  • lung neoplasms (1)
  • lymphocytes (3)
  • macrophages (1)
  • mice (2)
  • promotes tumor (1)
  • protein human (1)
  • rna (1)
  • signal (1)
  • Sizes of these terms reflect their relevance to your search.

    The master regulator of neuroendocrine differentiation, achaete-scute complex homolog 1 (ASCL1) defines a subgroup of lung adenocarcinoma. However, the mechanistic role of ASCL1 in lung tumorigenesis and its relation to the immune microenvironment is principally unknown. Here, the immune landscape of ASCL1-positive lung adenocarcinomas was characterized by immunohistochemistry. Furthermore, ASCL1 was transduced in mouse lung adenocarcinoma cell lines and comparative RNA-sequencing and secretome analyses were performed. The effects of ASCL1 on tumorigenesis were explored in an orthotopic syngeneic transplantation model. ASCL1-positive lung adenocarcinomas revealed lower infiltration of CD8+, CD4+, CD20+, and FOXP3+ lymphocytes and CD163+ macrophages indicating an immune desert phenotype. Ectopic ASCL1 upregulated cyclin transcript levels, stimulated cell proliferation, and enhanced tumor growth in mice. ASCL1 suppressed secretion of chemokines, including CCL20, CXCL2, CXCL10, and CXCL16, indicating effects on immune cell trafficking. In accordance with lower lymphocytes infiltration, ASCL1-positive lung adenocarcinomas demonstrated lower abundance of CXCR3-and CCR6-expressing cells. In conclusion, ASCL1 mediates its tumor-promoting effect not only through cell-autonomous signaling but also by modulating chemokine production and immune responses. These findings suggest that ASCL1-positive tumors represent a clinically relevant lung cancer entity. Copyright © 2020 Elsevier B.V. All rights reserved.


    Naoya Miyashita, Masafumi Horie, Yu Mikami, Hirokazu Urushiyama, Kensuke Fukuda, Kazuko Miyakawa, Hirotaka Matsuzaki, Kosuke Makita, Yasuyuki Morishita, Hiroaki Harada, Max Backman, Cecilia Lindskog, Hans Brunnström, Patrick Micke, Takahide Nagase, Akira Saito. ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma. Cancer letters. 2020 Oct 01;489:121-132

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32534174

    View Full Text